Skip to main content

Table 3 Univariate analysis of PrEP acceptability according to facilitators and obstacles, Benin

From: Acceptability of pre-exposure prophylaxis for HIV prevention: facilitators, barriers and impact on sexual risk behaviors among men who have sex with men in Benin

  Average ± standard deviation Acceptability
Yes (5)
N = 143
No (4 + 3 + 2 + 1)
N = 257
ORa CI 95% p
n(%) n(%)
Facilitators
 Not having to pay for PrEP 4.48 ± 0.58      
  5   116 (81.1) 88(34.3) 9.45 3.36–26.62 <.0001
  (4 + 3 + 2 + 1)   27 (18.9) 169(65.7) 1   
 Access to free HIV testing 4.46 ± 0.49      
  5   104(72.7) 82(31.9) 7.19 2.90–17.81 <.0001
  (4 + 3 + 2 + 1)   39(27.3) 175(68.1) 1   
 Access to free healthcare/sexual life supervision 4.45 ± 0.51      
  5   98(68.5) 84(32.7) 5.13 2.24–11.73 0.001
  (4 + 3 + 2 + 1)   45(31.5) 173(67.3) 1   
 Access to individual support and support around the use of PrEP 4.40 ± 0.57      
  5   100(69.9) 74(28.8) 7.04 2.65–18.67 <.0001
  (4 + 3 + 2 + 1)   43(30.1) 183(71.2) 1   
 Access to information on the use of PrEP 4.61 ± 0.53      
  5   115(80.4) 138(53.7) 4.65 1.32–16.37 0.01
  (4 + 3 + 2 + 1)   28(19.6) 119(46.3) 1   
 Access to support or counseling about my sexual life 4.38 ± 0.63      
  5   99(69.2) 74(28.8) 4.41 1.80–10.79 0.001
  (4 + 3 + 2 + 1)   44(30.8) 183(71.2) 1   
 Not having to go to the casual doctor for the PrEP 3.78 ± 0.98      
  (5 + 4)   113(79.1) 192(74.7) 1.02 0.37–2.82 0.95
  (3 + 2 + 1)   30(20.9) 65(25.3) 1   
 Access to group memberships information on PrEP use 4.18 ± 0.72      
  (5 + 4)   130(90.9) 241(93.8) 0.53 0.21–1.31 0.17
  (3 + 2 + 1)   13(9.1) 16(6.2) 1   
 Drug availability 4.80 ± 0.40      
  5   134(93.7) 190(73.9) 9.97 1.73–57.32 0.01
  (4 + 3 + 2 + 1)   9(6.3) 67(26.1) 1   
 Drug accessibility at the level of MSM networks 4.18 ± 1.01      
  5   125(87.4) 73(28.4) 15.14 3.89–58.95 <.0001
  (4 + 3 + 2 + 1)   18(12.6) 184(71.6) 1   
 Self-protection concern 4.18 ± 0.86      
  (5 + 4)   126(88.1) 207(80.5) 1.16 0.25–5.32 0.84
  (3 + 2 + 1)   17(11.9) 50(19.5) 1   
 Possibilities of Multiple partnerships 3.26 ± 1.12      
  (5 + 4)   93(65.0) 80(31.1) 1.78 0.56–5.63 0.32
  (3 + 2 + 1)   50(35.0) 177(68.89) 1   
 Lack of constraints during drug procurement 4.35 ± 0.66      
  (5 + 4)   130(90.9) 245(95.3) 0.89 0.52–1.55 0.69
  (3 + 2 + 1)   13(9.1) 12(4.7) 1   
 Sex possibilities with HIV-Positive 301 ± 1.03      
  (5 + 4)   66(46.2) 59(23) 2.09 1.05–4.16 0.03
  (3 + 2 + 1)   77(53.8) 198(77) 1   
Obstacles
 Concerns about PrEP long-term effects on my health 3.87 ± 1.01      
  (5 + 4)   99(69.2) 225(87.5) 0.38 0.11–1.29 0.12
  (3 + 2 + 1)   44(30.7) 32(12.5) 1   
 Concern about the fact that if I become infected by HIV, some ARV will no longer be efficient because they would have been taken as PrEP 3.57 ± 1.06      
  (5 + 4)   78(54.5) 151(58.7) 0.47 0.11–1.91 0.29
  (3 + 2 + 1)   65(45.5) 106(41.3) 1   
 Concern about the fact that PrEP does not provide a complete protection against HIV 3.78 ± 0.99      
  (5 + 4)   90(62.9) 205(79.8) 0.51 0.14–1.89 0.31
  (3 + 2 + 1)   53(37.1) 52(20.2) 1   
 Taking a drug every day 3.53 ± 1.01      
  (5 + 4)   83(58.0) 192(74.7) 0.31 0.09–1.03 0.05
  (3 + 2 + 1)   60(42.0) 65(25.3) 1   
 Concern that taking PrEP could make me more likely to have sex without condom 3.33 ± 0.96      
  (5 + 4)   78(54.5) 140(54.5) 0.77 0.17–3.45 0.73
  (3 + 2 + 1)   65(45.5) 117(45.5) 1   
 Concerns that having to take PrEP means that I put myself at risk for HIV 2.97 ± 1.06      
  (5 + 4)   26(18.2) 130(50.6) 0.16 0.06–0.41 0.002
  (3 + 2 + 1)   117(81.8) 127(49.4) 1   
 PrEP could make my partners expect to have anal sex without condom with me 3.47 ± 0.93      
  (5 + 4)   84(58.7) 162(64) 0.46 0.11–1.91 0.28
  (3 + 2 + 1)   59(41.3) 95(36) 1   
 Concerns that people will see me taking drug and will think I have HIV 3.79 ± 1.01      
  (5 + 4)   88(61.5) 220(85.6) 0.33 0.14–0.77 0.01
  (3 + 2 + 1)   55(38.5) 37(14.4) 1   
 Concerns that people will see me taking drug and will want to know why I’m taking it 3.67 ± 1.05      
  (5 + 4)   74(51.7) 221(86.0) 0.29 0.08–1.05 0.05
  (3 + 2 + 1)   69(48.3) 36(14.0) 1   
 Having to talk to my doctor about my sex life. 2.89 ± 1.14      
  (5 + 4)   60(42.0) 74(28.8) 1.44 0.58–3.57 0.42
  (3 + 2 + 1)   83(58.0) 183(71.2) 1   
 Binding procedures for the drug procurement 4.19 ± 0.79      
  (5 + 4)   117(81.8) 245(95.3) 0.34 0.12–0.93 0.03
  (3 + 2 + 1)   26(18.2) 12(4.7) 1   
 Size and Taste of drug 3.81 ± 1.06      
  (5 + 4)   93(65.3) 219(85.21) 0.32 0.11–0.91 0.03
  (3 + 2 + 1)   50(34.7) 38(14.79) 1   
 Fee-paying drug 4.27 ± 0.76      
  (5 + 4)   125(87.4) 248(96.5) 0.44 0.15–1.33 0.14
  (3 + 2 + 1)   18(12.6) 9(3.5) 1   
 Concern that PrEP may lead to prostitution 3.5 ± 1.08      
  (5 + 4)   98(68.5) 150(58.7) 1.01 0.18–5.55 0.98
  (3 + 2 + 1)   45(31.5) 107(41.3) 1   
 Concern that PrEP might encourage to be unfaithful, 3.49 ± 1.13      
  (5 + 4)   101(70.6) 149(58.0) 1.29 0.24–6.78 0.75
  (3 + 2 + 1)   42(29.4) 108(42.0) 1   
 Partner’s disagreement because I’m taking PrEP 3.08 ± 1.11      
  (5 + 4)   54(37.8) 138(53.7) 0.28 0.06–1.27 0.10
  (3 + 2 + 1)   89(62.2) 119(46.3) 1   
 The unresponsive attitude of MSM community towards PrEP, 3.39 ± 1.18      
  (5 + 4)   70(49.0) 159(61.9) 0.37 0.07–1.83 0.22
  (3 + 2 + 1)   73(51.0) 98(38.1) 1   
 PrEP as source of discrimination in health centers 3.75 ± 0.99      
  (5 + 4)   93(65.0) 214(83.3) 0.41 0.10–1.74 0.23
  (3 + 2 + 1)   50(34.0) 43(16.7) 1   
 Concern that PrEP may increase risk-taking (e.g: increase in unprotected sex, number of sexual partners, etc) 3.86 ± 0.96      
  (5 + 4)   89(62.2) 227(88.3) 0.36 0.12–1.12 0.07
  (3 + 2 + 1)   54(37.8) 30(11.7) 1   
 Concern that PrEP may increase the risk of contracting sexually transmitted infections other than HIV 4 ± 0.99      
  (5 + 4)   101(70.6) 230(89.5) 0.55 0.14–2.09 0.38
  (3 + 2 + 1)   42(29.4) 27(10.5) 1   
  1. aweighted odds ratios (probability weights generated by RDS Analyst